Intervacc AB Stock

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 02:00:00 04/09/26 am AEST			5-day change	1st Jan Change
1.134 ^SEK	+3.66%		+5.39%	+22.73%

21/08	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Calendar Thursday, August 20	FW

Analysts' recommendations : Intervacc AB

20/05/24	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/02/24	Penser lowers Intervacc's motivated value	FW
17/11/23	Penser makes minor estimate adjustments in Intervacc	FW
04/05/23	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/02/23	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors : Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	05/02/2026
Jan Persson DFI	Director of Finance/CFO	-	06/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	11/06/2020

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	13/05/2026
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	01/01/2024
Björn Ingemar Odlander BRD	Director/Board Member	68	01/01/2025

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
03/09/26	SEK 1.134	+3.66%	213,785
02/09/26	SEK 1.094	+0.92%	165,625
01/09/26	SEK 1.084	+2.26%	162,363
31/08/26	SEK 1.060	+1.34%	172,504
28/08/26	SEK 1.046	-2.24%	142,135

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	386M 40.52M 34.86M 32.74M 29.97M 55.91M 3.83B 56.31M 151M 1.96B 152M 149M 6.38B	P/E 2026 *	-1.01x	P/E 2027 *	-1.01x
Enterprise Value	297M 31.19M 26.83M 25.2M 23.07M 43.04M 2.95B 43.34M 116M 1.51B 117M 115M 4.91B	EV / Sales 2026 *	14.2x	EV / Sales 2027 *	10.8x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	IVACC	Delayed
Deutsche Boerse AG	2E9	Delayed
Börse Stuttgart	2E9	Delayed

21/08	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Calendar Thursday, August 20	FW
31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
29/07	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
29/07	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
15/05	Sweden's Intervacc Elects New Chair	MT
15/05	Appoints Emil Billbäck as chairman	RE
14/05	Intervacc elects Emil Billbäck as chairperson of board	RE
14/05	Intervacc AB Announces Board Changes	CI
13/05	Intervacc Q1 net sales down at SEK 3.4 million	RE
13/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

01/09	Intervacc: Highlights from DNB Carnegie’s Micro Cap Day	AQ
24/08	Intervacc (Q2 Review): Key catalysts nearing	AQ
21/08	Intervacc: In the right direction – Q2 review	AQ
20/08	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ
30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ

1 day	+3.66%
1 week	+5.39%
Current month	+6.98%
1 month	-10.71%
3 months	-6.90%
6 months	+83.50%
Current year	+22.73%

Intervacc AB Stock

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Valuation : Intervacc AB

Chart: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations : Intervacc AB

Press Releases : Intervacc AB

Quotes and Performance

Price Extremes

Managers and Directors : Intervacc AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 week	1.03	1.14
1 month	1	1.27
Current year	0.57	1.46
1 year	0.57	1.46
3 years	0.57	10.46
5 years	0.57	76
10 years	0.57	95.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/2/25	Jan Persson	Free	Chief Financial Officer	929,208	1.2269%
17/2/25	Jonas Sohlman	Buy	Chief Executive Officer	135,000	0.1783%
17/2/25	Jan-Ingmar Flock	Sell	Chief Executive Officer	278,820	0.3681%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB	+3.66%	+5.39%	-3.90%	-73.44%	38.75M
WUXI APPTEC CO., LTD.	+0.41%	-1.65%	+39.85%	+95.40%	68.87B
ARGENX SE	+1.31%	+1.65%	+50.56%	+90.80%	65.29B
INSMED INCORPORATED	+0.04%	+1.84%	-12.81%	+459.54%	27.65B
WUXI BIOLOGICS (CAYMAN) INC.	+2.97%	-0.10%	+41.86%	+14.84%	25.77B
BIONTECH SE	-0.90%	-8.60%	+2.25%	-15.50%	26.08B
GENMAB A/S	+1.01%	+1.76%	+32.99%	-17.16%	20.14B
PHARMAESSENTIA CORPORATION	+3.45%	-14.83%	+225.22%	+389.50%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.77%	-4.55%	-0.36%	+549.41%	15.03B
EXELIXIS, INC.	+1.03%	+5.40%	+59.04%	+160.03%	14.5B
Average	+1.37%	-2.03%	+43.47%	+165.34%	28.04B
Weighted average by Cap.	+0.98%	-1.63%	+43.43%	+149.95%

	2026 *	2027 *
Net sales	21M 2.2M 1.89M 1.78M 1.63M 3.04M 208M 3.06M 8.18M 107M 8.27M 8.08M 346M	30M 3.15M 2.71M 2.54M 2.33M 4.34M 297M 4.37M 11.69M 152M 11.81M 11.55M 495M
Net income	-82.45M -8.64M -7.44M -6.98M -6.39M -11.93M -817M -12.01M -32.12M -419M -32.46M -31.74M -1.36B	-83.65M -8.77M -7.54M -7.09M -6.49M -12.1M -829M -12.19M -32.59M -425M -32.93M -32.2M -1.38B
Net Debt	-89M -9.33M -8.03M -7.54M -6.9M -12.88M -882M -12.97M -34.67M -452M -35.04M -34.26M -1.47B	-61M -6.4M -5.5M -5.17M -4.73M -8.83M -604M -8.89M -23.77M -310M -24.01M -23.48M -1.01B